Catalyst Dossier · compiled by CeliA 🧫

Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR (JNGHF)

Biotechnology · market cap —

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-30 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

The catalyst path

2026-07-30 (est.)Phase 3 · TACE+Camrelizumab+Apatinib mesylateimp 9/10
2026-07-30 (est.)Phase 2 · JSKN003imp 7/10
2026-07-31 (est.)Phase 3 · Rivoceranib (Apatinib)imp 9/10
2026-10-31 (est.)Phase 3 · SHR6390imp 9/10
2026-11-15 (est.)Phase 2 · SHR-A1811 combined with Pyrotinib.imp 7/10
2026-12-15 (est.)Phase 2 · HRS-6209 Capsulesimp 7/10
2026-12-15 (est.)Phase 3 · Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotideimp 9/10
2026-12-31 (est.)Phase 3 · Pyrotinib in combination with Capecitabine.imp 9/10

Pipeline

Asset	Phase	Indication
HRS-4357 injection	Phase 3	PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
Propofol Injection.	Phase 2	Local Anesthesia Assisted Sedation
SHR0302 Tablets	Phase 2	Non-segmental Vitiligo
Apatinib	Phase 3	Carcinoma, Hepatocellular
APL-1202 treatment	Phase 2	Non-muscle Invasive Bladder Cancer
RSS0343 Tabella	Phase 2	Adolescent Asthma
X0002 Spray	Phase 3	KNEE OSTEOARTHRITIS
SHR-1020	Phase 2	Recurrent or Metastatic Cervical Cancer
KN026 combination	Phase 2	HER2-positive Solid Tumors
mFOLFIRINOX	Phase 2	Advanced Pancreatic Cancer
benzbromarone	Phase 2	Hyperuricemia
JSKN016	Phase 2	Inoperable Locally Advanced HER2-Negative Breast Cancer
Morphine	Phase 3	Pain
SHR2554/CHOP	Phase 2	Peripheral T-cell Lymphoma
SP2086(50 mg q.d.)/Metformin	Phase 2	Type 2 Diabetes
KN019, 5mg/kg	Phase 2	Rheumatoid Arthritis
HR18042	Phase 2	Moderate to Severe Acute Pain
KN026 10 mg/kg QW	Phase 2	Gastric/Gastroesophageal Junction Cancer
JSKN003	Phase 3	Advanced Solid Tumor
Nab-paclitaxel	Phase 2	Triple-negative Breast Cancer

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for JNGHF (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.